| Belzutifan for renal cell carcinoma in von Hippel–Lindau disease E Jonasch, F Donskov, O Iliopoulos, WK Rathmell, VK Narayan, ... New England Journal of Medicine 385 (22), 2036-2046, 2021 | 358 | 2021 |
| The value of 68Ga-DOTATATE PET/CT in diagnosis and management of neuroendocrine tumors compared to current FDA approved imaging modalities: a review of literature A Mojtahedi, S Thamake, I Tworowska, D Ranganathan, ES Delpassand American journal of nuclear medicine and molecular imaging 4 (5), 426, 2014 | 219 | 2014 |
| Alendronate coated poly-lactic-co-glycolic acid (PLGA) nanoparticles for active targeting of metastatic breast cancer SI Thamake, SL Raut, Z Gryczynski, AP Ranjan, JK Vishwanatha Biomaterials 33 (29), 7164-7173, 2012 | 196 | 2012 |
| Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: A phase 1 trial and biomarker analysis TK Choueiri, TM Bauer, KP Papadopoulos, ER Plimack, JR Merchan, ... Nature medicine 27 (5), 802-805, 2021 | 185 | 2021 |
| Reciprocal regulation of annexin A2 and EGFR with Her-2 in Her-2 negative and herceptin-resistant breast cancer PK Shetty, SI Thamake, S Biswas, SL Johansson, JK Vishwanatha PLoS One 7 (9), e44299, 2012 | 81 | 2012 |
| Surface functionalization of PLGA nanoparticles by non-covalent insertion of a homo-bifunctional spacer for active targeting in cancer therapy SI Thamake, SL Raut, AP Ranjan, Z Gryczynski, JK Vishwanatha Nanotechnology 22 (3), 035101, 2010 | 69 | 2010 |
| Inhibition of triple-negative and Herceptin-resistant breast cancer cell proliferation and migration by Annexin A2 antibodies P Chaudhary, SI Thamake, P Shetty, JK Vishwanatha British journal of cancer 111 (12), 2328-2341, 2014 | 55 | 2014 |
| A competitive hexapeptide inhibitor of annexin A2 prevents hypoxia-induced angiogenic events M Valapala, SI Thamake, JK Vishwanatha Journal of cell science 124 (9), 1453-1464, 2011 | 55 | 2011 |
| Phase I/II study of the oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC). TK Choueiri, ER Plimack, TM Bauer, JR Merchan, KP Papadopoulos, ... Journal of Clinical Oncology 38 (6_suppl), 611-611, 2020 | 52 | 2020 |
| Phase II study of the oral HIF-2 alpha inhibitor MK-6482 for Von Hippel-Lindau disease-associated renal cell carcinoma. E Jonasch, F Donskov, O Iliopoulos, WK Rathmell, V Narayan, ... | 52 | 2020 |
| Assessment of vulnerable atherosclerotic and fibrotic plaques in coronary arteries using 68Ga-DOTATATE PET/CT A Mojtahedi, A Alavi, S Thamake, R Amerinia, D Ranganathan, ... American journal of nuclear medicine and molecular imaging 5 (1), 65, 2015 | 46 | 2015 |
| Rationalizing the use of functionalized poly-lactic-co-glycolic acid nanoparticles for dendritic cell-based targeted anticancer therapy RA Kokate, P Chaudhary, X Sun, SI Thamake, S Maji, R Chib, ... Nanomedicine 11 (5), 479-494, 2016 | 38 | 2016 |
| The oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC): Updated follow-up of a phase I/II study. TM Bauer, TK Choueiri, KP Papadopoulos, ER Plimack, JR Merchan, ... Journal of clinical oncology 39 (6_suppl), 273-273, 2021 | 28 | 2021 |
| Results from a phase I expansion cohort of the first-in-class oral HIF-2α inhibitor PT2385 in combination with nivolumab in patients with previously treated advanced RCC. BI Rini, LJ Appleman, RA Figlin, ER Plimack, JR Merchan, K Wang, ... Journal of clinical oncology 37 (7_suppl), 558-558, 2019 | 27 | 2019 |
| A sustained release formulation of chitosan modified PLCL: poloxamer blend nanoparticles loaded with optical agent for animal imaging AP Ranjan, K Zeglam, A Mukerjee, S Thamake, JK Vishwanatha Nanotechnology 22 (29), 295104, 2011 | 25 | 2011 |
| Radiosynthesis of clinical doses of 68Ga-DOTATATE (GalioMedix™) and validation of organic-matrix-based 68Ge/68Ga generators I Tworowska, D Ranganathan, S Thamake, E Delpassand, A Mojtahedi, ... Nuclear medicine and biology 43 (1), 19-26, 2016 | 24 | 2016 |
| A Comparative Study of Phytoestrogen Action in Mitigating Apoptosis Induced by Oxidative Stress AJ ONDRICEK, AK KASHYAP, SI THAMAKE, JK VISHWANATHA In Vivo 26 (5), 765-775, 2012 | 21 | 2012 |
| Studies on solvatochromic properties of aminophenylstyryl-quinolinum dye, LDS 798, and its application in studying submicron lipid based structure P Sarkar, R Luchowski, S Raut, N Sabnis, A Remaley, AG Lacko, ... Biophysical chemistry 153 (1), 61-69, 2010 | 17 | 2010 |
| Enhancement of anti-tumor effect of particulate vaccine delivery system by ‘bacteriomimetic’CpG functionalization of poly-lactic-co-glycolic acid nanoparticles RA Kokate, SI Thamake, P Chaudhary, B Mott, S Raut, JK Vishwanatha, ... Nanomedicine 10 (6), 915-929, 2015 | 11 | 2015 |
| Treatment of high grade metastatic neuroendocrine tumor (mNET) with peptide receptor radionuclide therapy (PRRT): Retrospective analysis in a single referral center. T Armaghany, G Vahdati, S Thamake, M Hamidi, R Amerinia, ... Journal of Clinical Oncology 33 (15_suppl), e15175-e15175, 2015 | 10 | 2015 |
Alireza Mojtahedi, MDBeth Israel Deaconess Medical Center, Harvard Medical SchoolVerified email at bidmc.harvard.edu
